Article Type
Changed
Thu, 03/17/2022 - 17:08

Key clinical point: Almost one-third of patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) experience acute exacerbation (AE), which significantly affects overall survival.

Major finding: Overall, AE was experienced by 28.1% of patients with RA-ILD, with the 5-year cumulative incidence being 29.4%. The occurrence of AE was significantly associated with a higher risk for mortality (adjusted hazard ratio 2.423; P < .001).

Study details: The findings come from a retrospective analysis involving 310 patients with RA-ILD.

Disclosures: This study was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science and Technology. All the authors declared no conflicts of interest.

Source: Kwon BS et al. Chest. 2022 (Jan 11). Doi: 10.1016/j.chest.2022.01.007

Publications
Topics
Sections

Key clinical point: Almost one-third of patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) experience acute exacerbation (AE), which significantly affects overall survival.

Major finding: Overall, AE was experienced by 28.1% of patients with RA-ILD, with the 5-year cumulative incidence being 29.4%. The occurrence of AE was significantly associated with a higher risk for mortality (adjusted hazard ratio 2.423; P < .001).

Study details: The findings come from a retrospective analysis involving 310 patients with RA-ILD.

Disclosures: This study was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science and Technology. All the authors declared no conflicts of interest.

Source: Kwon BS et al. Chest. 2022 (Jan 11). Doi: 10.1016/j.chest.2022.01.007

Key clinical point: Almost one-third of patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) experience acute exacerbation (AE), which significantly affects overall survival.

Major finding: Overall, AE was experienced by 28.1% of patients with RA-ILD, with the 5-year cumulative incidence being 29.4%. The occurrence of AE was significantly associated with a higher risk for mortality (adjusted hazard ratio 2.423; P < .001).

Study details: The findings come from a retrospective analysis involving 310 patients with RA-ILD.

Disclosures: This study was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science and Technology. All the authors declared no conflicts of interest.

Source: Kwon BS et al. Chest. 2022 (Jan 11). Doi: 10.1016/j.chest.2022.01.007

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: RA March 2022
Gate On Date
Thu, 02/24/2022 - 16:45
Un-Gate On Date
Thu, 02/24/2022 - 16:45
Use ProPublica
CFC Schedule Remove Status
Thu, 02/24/2022 - 16:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Activity Salesforce Deliverable ID
325029.34
Activity ID
77974
Product Name
Clinical Edge Journal Scan
Product ID
124
Supporter Name /ID
RINVOQ [ 5260 ]